Agilus Diagnostics, India’s largest and most trusted diagnostics network, proudly announces the introduction of the Claudin 18.2 test—a groundbreaking diagnostic innovation poised to redefine cancer care. This milestone underscores Agilus Diagnostics’ dedication to advancing diagnostic excellence and supporting personalized medicine in oncology.
Gastric cancer ranks as the fifth most common cancer among men and the seventh among women in India. Known for its aggressive nature, gastric cancer is the second leading cause of cancer-related deaths among Indians aged 15 to 44. With a pressing need for enhanced therapeutic options, the Claudin 18.2 test emerges as a crucial tool in improving patient outcomes.
As per the press release, this cutting-edge diagnostic test precisely identifies the Claudin 18.2 protein, a vital biomarker associated with gastric, pancreatic, and other cancers. By offering unparalleled accuracy in biomarker detection, it empowers oncologists to identify patients eligible for targeted therapies. This innovation paves the way for improved cancer treatment strategies and reinforces the principles of personalized medicine.
Expert Insights on the Launch
Dr. Anand K, Managing Director & CEO of Agilus Diagnostics, remarked, “Claudin 18.2 is a game-changing biomarker in modern oncology, especially for gastric cancer patients. With an approved targeting antibody, this test enhances diagnostic precision and bridges the gap to personalized treatment approaches. It enables clinicians to tailor therapies to individual patients, thereby significantly improving outcomes. Agilus Diagnostics is proud to bring this advanced diagnostic tool to India, reaffirming our commitment to transforming healthcare with innovative solutions.”
Adding to this, Dr. Kunal Sharma, Associate Director & HOD of the Histopathology Center of Excellence at Agilus Diagnostics, highlighted, “In October 2024, the FDA approved zolbetuximab-clzb, a Claudin 18.2-directed antibody therapy, for first-line treatment of advanced HER2-negative gastric and gastroesophageal junction (GEJ) cancers expressing CLDN18.2. The VENTANA CLDN18 assay was also approved as a companion diagnostic to identify eligible patients. By introducing the FDA-approved Claudin 18.2 test, Agilus Diagnostics aligns with these global advancements, bringing cutting-edge diagnostics and treatment options to Indian oncology.”
Why Claudin 18.2 is a Game-Changer
- Precision Diagnosis: Accurately detects the Claudin 18.2 protein in tumor samples, ensuring reliable results.
- Personalized Treatment: Identifies patients suitable for Claudin 18.2-targeted therapies, improving treatment precision.
- Enhanced Outcomes: Enables targeted interventions that can slow cancer progression and improve survival rates.
Agilus Diagnostics remains at the forefront of laboratory medicine by integrating advanced technology and research into its services. With a robust infrastructure that includes AI-powered digital pathology and a commitment to innovation, the organization is shaping the future of diagnostic care in India.